Co-primary Endpoints: Moderate to Severe Plaque PsO | TREMFYA® (guselkumab) HCP

TREMFYA® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

7 OUT OF 10 PATIENTS ACHIEVED PASI 90 AT WEEK 16 AFTER JUST 3 INJECTIONS1,2

VOYAGE 1*

Results at Week 16

VOYAGE 2: CO-PRIMARY ENDPOINTS AT WEEK 16 vs PLACEBO1,3‬‬‬‬‬‬‬‬*

IGA=Investigator's Global Assessment, IGA score of cleared (0) or minimal (1) using a 5-point scale of overall disease severity; PASI=Psoriasis Area and Severity Index.

*Nonresponder imputation (NRI) methods were used for analysis.

P<0.001 vs placebo.

References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417. 3. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418‑431.